Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two…
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of…
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing…
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused…
LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized…
Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of…
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnosticsThis partnership…
JOHNSON CITY, Tenn., May 29, 2025 /PRNewswire/ -- Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement…
BOSTON, May 29, 2025 /PRNewswire/ -- Outcomes4Me Inc., the developer of the leading direct-to-patient, AI-driven platform transforming the cancer care…
HYDERABAD, India and VANCOUVER, BC, May 29, 2025 /PRNewswire/ -- Mapmygenome, an AI-driven leader in genomics and personalized health, announced…